SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

ARO-DIMER-PA

ARWR·ARROWHEAD PHARMACEUTICALS, INC.
BULLISH
Drug Impact Rating4/10
Trial phase
Phase 1/2a
Time to market
A Phase 1/2a SAD portion is complete and the MAD portion is enrolling; assuming positive data, Phase 2/3 would likely follow. Commercial approval, if successful, is likely several years away (3+ years).
Why 4/10
No hard binary catalyst (PDUFA, pivotal readout) is scheduled in the next 12 months for ARO-DIMER-PA; the Phase 1/2a MAD data readout is the next major milestone but lacks a confirmed date. Arrowhead is now a commercial-stage company (REDEMPLO approved), so ARO-DIMER-PA is one of several pipeline assets rather than the sole value driver, capping the impact score at 4.
Actionable Insight BULLISH

ARO-DIMER-PA delivered promising Phase 1 SAD data at AHA 2026, validating Arrowhead's dual-gene RNAi platform, but the stock is down 50% from its 52-week high amid institutional selling and pre-commercial cash-burn concerns. The next catalyst is the MAD portion data, which will test durability and safety of repeat dosing. With a mean analyst price target of $106 implying 122% upside, sentiment is bullish on the pipeline broadly, but no binary catalyst is imminent.

Price Chart

Loading chart...

Executive Summary

ARO-DIMER-PA is Arrowhead Pharmaceuticals' investigational first-in-class dual-functional RNAi drug designed to silence both PCSK9 and APOC3 from a single injection, aiming to lower LDL cholesterol and triglycerides simultaneously in mixed hyperlipidemia. Phase 1 single-dose data presented at AHA 2026 showed 54-65% LDL reductions and 73-78% triglyceride reductions with one dose. The multiple ascending dose portion of the Phase 1/2a study is ongoing, with no imminent regulatory catalyst. Arrowhead is now a commercial-stage company with FDA-approved REDEMPLO, and analysts are bullish on the stock (mean PT $106, ~122% upside), though the stock has fallen sharply from its highs and faces cash-burn and competitive headwinds.

How It Works

ARO-DIMER-PA is a first-of-its-kind RNA interference (RNAi) drug that silences two genes (PCSK9 and APOC3) with a single molecule, using Arrowhead's TRiM delivery platform. PCSK9 is a protein that controls LDL (bad) cholesterol clearance; APOC3 is a protein that controls triglyceride metabolism. By targeting both at once from one injection, the drug aims to lower both LDL cholesterol and triglycerides simultaneously in patients with mixed hyperlipidemia at risk for cardiovascular disease.

Trial Status

Arrowhead completed the single ascending dose (SAD) portion of a Phase 1/2a randomized, double-blind, placebo-controlled trial. Interim topline data was announced September 15, 2026, showing mean maximal reductions in serum PCSK9 of 72% and APOC3 of 88% from a single dose. Updated results were presented at the American Heart Association Scientific Sessions on November 7, 2026, showing mean LDL cholesterol reductions up to 65% and median triglyceride reductions up to 78% with a single injection. The multiple ascending dose (MAD) portion of the trial is ongoing.

The Two-Sided Case

▲ Bull Case4
ARO-DIMER-PA achieved clinical validation of Arrowhead's novel dimeric RNAi platform, demonstrating deep and durable dual-gene silencing from a single injection, with mean maximal reductions of 72% in PCSK9 and 88% in APOC3 in Phase 1 SAD data (BusinessWire, Sept 15, 2026).
At AHA 2026, ARO-DIMER-PA showed mean LDL-C reductions up to 65% and median triglyceride reductions up to 78%, which compare favorably to existing PCSK9 and APOC3 inhibitors that each target only one of the two pathways; the dual mechanism could become a best-in-class approach for mixed hyperlipidemia (TechTimes, Nov 7, 2026).
Analyst consensus is strongly bullish on ARWR: 20 analysts rate it Buy/Strong Buy with a mean price target of $106 (122% upside from $47.78), and RBC Capital and Stifel both reiterated positive ratings on Nov 13, 2026.
Arrowhead is now a commercial-stage company with FDA-approved REDEMPLO (plozasiran) for FCS, providing a commercial infrastructure and revenue base that reduces dilution risk for pipeline programs like ARO-DIMER-PA (FDA catalysts data, Nov 2025 approval).
▼ Bear Case5
ARO-DIMER-PA is very early stage (Phase 1/2a), with only single-dose data available; durability, safety at repeat dosing, and proof of cardiovascular outcomes are entirely unproven and represent significant clinical risk.
The PCSK9 inhibitor market is already crowded with approved biologics (Amgen's Repatha, Regeneron/Sanofi's Praluent) and oral alternatives in development; APOC3 antisense drugs from Ionis (olezar sen / TQJ230, now Novartis) are also in late-stage development, creating substantial competition.
ARWR stock has fallen roughly 50% from its 52-week high of $95.49 to $47.78; despite positive ARO-DIMER-PA data, the stock sold off on September 15, 2026 (sell-the-news reaction), suggesting high expectations were already priced in.
Short interest stands at 8.2% of outstanding shares with 8.54 days to cover (as of Oct 30, 2026), and several tracked institutional funds trimmed or exited ARWR positions in Q3 2026, including First Trust (-67% trim), 1832 Asset Management (full exit), and Renaissance Technologies (near-exit).
Arrowhead reported a fiscal 2026 loss of $5.11 per share with revenue declining from $829M to $444M, and the company is investing heavily in R&D across multiple pipeline programs, raising cash-burn concerns (MarketScreener, Nov 12, 2026).

Upcoming Catalysts

  • Phase 1/2a multiple ascending dose (MAD) data readout (date not yet announced)
  • Initiation of Phase 2 or registrational trial planning, dependent on MAD results

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARROWHEAD PHARMACEUTICALS, INC. 8-K ARWR ·Originating report

Sources · 5

Hover a chip for the title
1 businesswire.com2 morningstar.com3 msn.com4 techtimes.com5 marketscreener.com